Alamar Biosciences Shares Surge Following Upsized US IPO

Apr 17, 2026 16:41 UTC

Alamar Biosciences

Short term

Alamar Biosciences saw its stock price climb 33% on its first day of trading after pricing its IPO at the top of the expected range. The company raised $191 million to fund its protein biomarker diagnostic technology.

IPO priced at $17, the top of the $15-$17 range
Total capital raised reached $191 million
Offering size increased to 11.25 million shares from 9.38 million
Shares opened at $22.60, representing a 33% premium over the IPO price
Company focuses on protein biomarker detection for disease diagnosis

Alamar Biosciences Inc. experienced a strong market debut on Friday, with shares surging 33% following a successful upsized initial public offering in the United States. The medical device manufacturer specializes in the development of tools designed to detect protein biomarkers, which are critical for the early diagnosis and monitoring of various diseases. The company priced its offering at $17 per share, the upper limit of its marketed range of $15 to $17. Due to strong investor demand, Alamar increased the size of the offering to 11.25 million shares, up from the original plan of 9.38 million shares. This adjustment resulted in total proceeds of $191 million. Trading opened at $22.60 per share in New York, reflecting significant appetite for the company's diagnostic capabilities. The positive reception underscores investor interest in specialized medical device firms capable of improving disease detection through biomarker analysis.